Table 1 |
|||||||
|
Patient demographics |
|||||||
|
Patient no. |
Age (years) |
Tumor size (mm) |
Node status |
ER status |
PgR status |
Clinical response |
Pathological finding (after chemotherapy) |
|
|
|||||||
|
1 |
42 |
7 |
+ |
+ |
n/a |
CR |
No surgery |
|
2 |
37 |
50 |
+ |
+ |
n/a |
MRD |
No surgery |
|
3 |
50 |
19 |
+ |
+ |
n/a |
MRD |
DCIS only |
|
4 |
56 |
24 |
- |
- |
n/a |
MRD |
No surgery |
|
5 |
56 |
50 |
+ |
- |
n/a |
MRD |
DCIS only |
|
6 |
48 |
50 |
+ |
- |
n/a |
SD |
RID |
|
7 |
64 |
40 |
+ |
- |
- |
PR |
RID |
|
8 |
47 |
30 |
- |
+ |
n/a |
SD |
RID |
|
9 |
51 |
50 |
- |
+ |
n/a |
PR |
RID |
|
10 |
67 |
30 |
- |
- |
- |
SD |
RID |
|
|
|||||||
|
CR, complete clinical response (no residual palpable disease); ER, estrogen receptor; MRD, minimal residual disease (residual palpable irregularity that was too small to be measured); n/a, not available; PgR, progestrogen receptor; PR, partial response (more than 50% reduction in bidimensional measurement); SD, stable disease (between 50% reduction and 25% increase in bidimensional measurement); RID, residual invasive disease; DCIS, ductal carcinoma in situ. |
|||||||
|
Sotiriou et al. Breast Cancer Res 2002 4:R3 doi:10.1186/bcr433 |
|||||||
